IPHARMA Tirzepatide is an advanced, dual-acting research compound targeting both GIP and GLP-1 receptors. This 30mg (2.4ml) peptide is provided in a convenient, pre-filled peptide pen format, specifically engineered for precision in laboratory settings. It is widely utilized in studies exploring metabolic regulation, insulin signaling, glucose homeostasis, and energy balance in controlled experimental models.
Key Research Benefits
Appetite Control: Supports the study of reduced food cravings and suppressed appetite.
Satiety Support: Helps research models promote feelings of fullness and better portion control.
Metabolic Regulation: Assists in studying blood sugar balance and the optimization of insulin signaling pathways.
Body Composition: Provides a specialized tool for investigating effective fat loss and body composition management.
Energy Balance: Designed to help researchers explore advanced pathways in systemic metabolic health and energy homeostasis.